CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Seelos Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Seelos Therapeutics Inc
300 PARK AVENUE, 2ND FLOOR
Phone: (646) 293-2100p:646 293-2100 NEW YORK, NY  10022  United States Ticker: SEELQSEELQ
Filed for Bankruptcy on 11/16/2024
Case #24-11987, filed in the U.S. Bankruptcy Court for the Southern District of New York (Manhattan)
Business Summary
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard W.Pascoe 60 4/29/2024 3/18/2013
President, Chief Executive Officer, Director RajMehra 65 4/29/2024 1/24/2019
Chief Financial Officer Michael J.Golembiewski 53 9/1/2021 9/1/2021
Independent Director MargaretDalesandro 78 9/1/2021 9/1/2021
Independent Director Brian W.Lian 58 1/1/2020 1/24/2019

Business Names
Business Name
APRI
Apricus Bio
Apricus Biosciences, Inc.
11 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 8/6/2024)
Outstanding Shares: 435,958 (As of 9/27/2024)
Shareholders: 104
Stock Exchange: OTC
Federal Tax Id: 870449967
Fax Number: (858) 436-8155
Email Address: tclemensen@rubensteinir.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 1, 2024